 Connection
Matthew Greenhawt to Omalizumab
This is a "connection" page, showing publications Matthew Greenhawt has written about Omalizumab.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.561 |
|
|
|
-
Greenhawt M, Shaker M. Keeping risk in context while rethinking the setting of asthma biologics in patient-centered care. Ann Allergy Asthma Immunol. 2020 08; 125(2):124-125.
Score: 0.690
-
Shaker M, Briggs A, Dbouk A, Dutille E, Oppenheimer J, Greenhawt M. Estimation of Health and Economic Benefits of Clinic Versus Home Administration of Omalizumab and Mepolizumab. J Allergy Clin Immunol Pract. 2020 02; 8(2):565-572.
Score: 0.661
-
Shaker M, Oppenheimer J, Wallace D, Lang DM, Rambasek T, Dykewicz M, Greenhawt M. Optimizing Value in the Evaluation of Chronic Spontaneous Urticaria: A Cost-Effectiveness Analysis. J Allergy Clin Immunol Pract. 2020 Jul - Aug; 8(7):2360-2369.e1.
Score: 0.166
-
Phipatanakul W, Mauger DT, Guilbert TW, Bacharier LB, Durrani S, Jackson DJ, Martinez FD, Fitzpatrick AM, Cunningham A, Kunselman S, Wheatley LM, Bauer C, Davis CM, Geng B, Kloepfer KM, Lapin C, Liu AH, Pongracic JA, Teach SJ, Chmiel J, Gaffin JM, Greenhawt M, Gupta MR, Lai PS, Lemanske RF, Morgan WJ, Sheehan WJ, Stokes J, Thorne PS, Oettgen HC, Israel E. Preventing asthma in high risk kids (PARK) with omalizumab: Design, rationale, methods, lessons learned and adaptation. Contemp Clin Trials. 2021 01; 100:106228.
Score: 0.045
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|